ArticleAndrology2023
Testosterone in males with COVID-19: a 12-month cohort study.
Article in Andrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Post-COVID syndrome's impact on sex life - results from a cross-sectional study.BMC public health · 2026Article
- Interplay Between Infectious Diseases and the Endocrine System: An Overview and Clinical Insights.Endocrinology, diabetes & metabolism · 2026Review
- The trigger-timing framework for long COVID: using symptom triggers and temporal patterns to guide mechanistic stratification and treatment planning.Frontiers in medicine · 2026Article
- COVID-19 infection may reduce serum testosterone levels and increase the risk of erectile dysfunction: A two-sample Mendelian randomization study.Investigative and clinical urology · 2025Article
- SARS-CoV-2-induced cytokine storm drives prolonged testicular injury and functional impairment in mice that are mitigated by dexamethasone.PLoS pathogens · 2025Article
- Repercussion of SARS-CoV-2 on the Sexual Function in Males: An Updated Review.Infectious disorders drug targets · 2025Review
- Hypopituitarism and COVID-19.Pituitary · 2024Review
- Causal associations between COVID-19 and erectile dysfunction: a Mendelian randomization study.The Journal of international medical research · 2024Article
- Article
- The International Virus Bioinformatics Meeting 2023.Viruses · 2023Article
- CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.Cell reports. Medicine · 2023Article
- The Potential Role of Hypothalamic Phospholipid Liposomes in the Supportive Therapy of Some Manifestations of Post-COVID-19 Condition: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Brain Fog.Journal of clinical medicine · 2023Article
- Pituitary and SARS CoV-2: An unremitting conundrum.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- Updates in the pathophysiology of COVID-19 infection in male reproductive and sexual health: a literature review.Frontiers in endocrinology · 2023Review
- Long-term effects of COVID-19 on the endocrine system - a pilot case-control study.Frontiers in endocrinology · 2023Article
- Testosterone in males with COVID-19: a 12-month cohort study.Andrology · 2023Article
- Abnormalities of Endocrine Function Tests in COVID-19-Recovered Individuals.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale patients with COVID-19 have been found with reduced serum total testosterone (tT) levels and with more severe clinical outcomes.
objectivesTo assess total testosterone (tT) levels and the probability of recovering eugonadal tT levels during a minimum 12-month timespan in a cohort of men who have been followed over time after the recovery from laboratory-confirmed COVID-19. MATERIALS AND
methodsDemographic, clinical and hormonal values were collected for the overall cohort. Hypogonadism was defined as tT ≤9.2 nmol/l. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics was used to compare hormonal levels at baseline versus 7-month (FU1) versus 12-month (FU2) follow-up, respectively. Multivariate cox proportional hazards regression model was used to identify the potential predictors of eugonadism recovery over time among patients with hypogonadism at the time of infection.
resultsOf the original cohort of 286 patients, follow-up data were available for 121 (42.3%) at FU1 and 63 (22%) patients at FU2, respectively. Higher median interquartile range (IQR) tT levels were detected at FU2 (13.8 (12.3-15.3) nmol/L) versus FU1 (10.2 [9.3-10.9] nmol/L) and versus baseline (3.6 [3.02-4.02] nmol/L) (all p < 0.0001), whilst both LH and E
conclusionsCirculating tT levels keep increasing over time in men after COVID-19. Still, almost 30% of men who recovered from COVID-19 had low circulating T levels suggestive for a condition of hypogonadism at a minimum 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.